EBS: Emergent BioSolutions Inc. Stock

by  •  • Comments Off on EBS: Emergent BioSolutions Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 481.16
Enterprise Value ($M) 993.86
Book Value ($M) 508.40
Book Value / Share 9.38
Price / Book 0.95
NCAV ($M) -308.00
NCAV / Share -5.68
Price / NCAV -1.56

Profitability (mra)
Return on Invested Capital (ROIC) -0.18
Return on Assets (ROA) -0.11
Return on Equity (ROE) -0.22

Liquidity (mrq)
Quick Ratio 1.47
Current Ratio 2.88

Balance Sheet (mrq) ($M)
Current Assets 661.40
Assets 1,477.80
Liabilities 969.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G Oak Hill Advisors Lp 6.39
11-08 13G/A Charles Schwab Investment Management Inc 4.20 -22.59
09-10 13G/A BlackRock, Inc. 3.70 -48.72
02-13 13G/A Vanguard Group Inc 5.73 12.40
01-23 13G/A State Street Corp 2.05 -6.10
01-18 13G/A Millennium Management Llc 4.00 -22.71

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-12-11 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-21 250,463 1,178,024 21.26
2024-11-20 274,607 960,262 28.60
2024-11-19 309,979 1,276,851 24.28
2024-11-18 701,094 2,484,229 28.22

(click for more detail)

Similar Companies
BHVN – Biohaven Ltd. BMY – Bristol-Myers Squibb Company
CTLT – Catalent, Inc. ELAN – Elanco Animal Health Incorporated
HYAC – Haymaker Acquisition Corp. 4


Financial data and stock pages provided by
Fintel.io